RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.240
+0.040 (3.33%)
At close: Jul 31, 2025, 4:00 PM
1.260
+0.020 (1.61%)
After-hours: Jul 31, 2025, 7:29 PM EDT
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
RenovoRx, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Shaun Bagai |
Contact Details
Address: 2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States | |
| Phone | 650 284 4433 |
| Website | renovorx.com |
Stock Details
| Ticker Symbol | RNXT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001574094 |
| CUSIP Number | 75989R107 |
| ISIN Number | US75989R1077 |
| Employer ID | 27-1448452 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaun R. Bagai | Chief Executive Officer, Secretary and Director |
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board and Chief Medical Officer |
| Leesa Gentry | Chief Clinical Officer |
| Robert Strasser | Vice President of Operations and Research & Development |
| Ronald B. Kocak CPA, CGMA | Vice President, Controller and Principal Accounting Officer |
| Ryan Witt | Senior Vice President and Head of Corporate Strategy and Partnerships |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 25, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 8, 2025 | SCHEDULE 13G | Filing |
| May 7, 2025 | SCHEDULE 13G | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |